Featured Courses
Examining a Complex Heart Failure Case
- 1 EBAC
Published:
Learning objectives
- Identify individuals likely to have HFpEF from initial presentation
- Refer suspected individuals for specialist assessment
- Initiate GDMT for HF as soon as patients are stable
- Initiate GDMT in HF regardless of EF and phenotype
- Initiate shared decision-making on complex HF patients with other members of the multidisciplinary team including cardiologists, GPs, nephrologists and diabetologists
CVD and Type 2 Diabetes: Navigating Therapeutic Boundaries in GLP-1 RA Use
- 2 EBAC
Published:
Learning objectives
- Describe the burden of ASCVD in type 2 diabetes
- Assign risk of future CV events to individuals with type 2 diabetes
- Identify appropriate patients for GLP-1 RA therapy based on clinical trial outcome data to reduce ASCVD risk
- Recall trial data of anti-diabetes medications that reduce ASCVD risk
- Recall the pleiotropic effects of GLP-1 RAs and how these may impact CV outcomes
- Describe how early adoption of anti-diabetes therapies with proven CV benefit can positively influence QOL
- Adopt anti-diabetic therapies with proven ASCVD benefit
Individualising Antithrombotic Strategies for Established CAD
- 1.00 European Board for Accreditation of Continuing Education for Health Professionals (EBAC)
Published:
Learning objectives
- Summarise current guidance for choosing antithrombotic therapy in established CAD
- Describe current gaps in clinical evidence and what is missing from current guidance
- Adopt an evidence-based approach for managing patients with ACS and CCS
HCM in Review: Highlights of 2022
- 0.25 AMA PRA Credit
Published:
Learning objectives
- Recall the efficacy and safety of existing HCM treatments
- Summarise results from ongoing trials with experimental treatments
Transcatheter Edge-to-Edge Repair: An Assessment of its Long-term Impact on Mitral Regurgitation
- 1.00 EBAC
Published:
Learning objectives
- Recall the long-term outcomes of TEER from real-world and RCT data
- Apply the results of real-world data to both simple and complex patients
- Describe how TEER is being used to benefit a range of patients with MR
HCM in Review: Assessing SCD Risk in HCM & Managing HCM With High Risk SCD
- 0.50 AMA PRA Credit
Published:
Learning objectives
- Recall risk factors associated with sudden cardiac death (SCD)
- Recall best practice approaches to prevent SCD according to guidelines and expert insight
- Stratify patients likely to benefit from invasive procedures versus pharmacological treatment
Changing Paradigms in Therapy to Unmet Needs
- 1 EBAC
Published:
Learning objectives
- Recall the utility of EF in heart failure treatment, patient selection and treatment response
- Identify alternative measures to EF for the purposes HF severity and therapeutic efficacy
- Incorporate quality of life measures for assessing therapeutic efficacy in HF
- Recall outcomes from heart failure trials from recent congress and publications and their impact on practice
Renal Denervation In The Real World: Practical Guidance For New Users
- 1 EBAC
Published:
Learning objectives
- Assess the current global burden of resistant hypertension
- Carry out appropriate assessments to identify resistant hypertension
- Identify patients most likely to benefit from RDN
- Recall the practical considerations for adopting RDN into routine practice
- Recall the latest data on RDN from recent clinical trials
SGLT-2 Inhibitors - Another Piece of the Puzzle in Heart Failure
- 1 EBAC
Published:
Learning objectives
- Recall the results of key trials in HFmrEF in different patients' sub-groups
- Describe how SGLT-2 inhibitors can be used across the range of LVEF
- Apply emerging diagnostic approaches for HFpEF and HFmrEF
- Implement best-practice strategies across the range of LVEF
Available Courses
A Review of Emerging ARNI Data in HFrEF
- 1.00 EBAC
Published:
Learning objectives
- Review updated data of ARNI therapy for HFrEF present at the ESC 2019;
- understand the current utilisation of ARNI therapy in HFrEF (guidelines and databases);
- interpret potential mechanistic data related to the clinical benefit of ARNI therapy including imaging and biomarker data;
- apply new data covering the utilization of ARNI therapy in complex patients including recently decompensated and hospitalized; patients
- Apply clinical and real-world evidence data for the treatment HFrEF with ARNI therapy.
ADVANCES IN IMAGING: OPTIMISING MR AND CT IN DAILY PRACTICE
- 2.00 EBAC
Published:
Learning objectives
- Interpret existing clinical and meta data for use of pre-procedural, image-aided ablation in ventricular arrhythmias
- Identify where pre-procedural imaging may complement the current ablation workflow in ventricular arrhythmias
- Recall the clinical benefits of quantitative, MRI-based approaches to evaluate ischaemia
- Apply quantitative CMR imaging to complement existing procedural workflows in revascularisation procedures
Convergent Procedure for Atrial Fibrillation
- 1.00 EBAC
Published:
Learning objectives
- Discuss the need for optimal approaches to atrial ablation and identify patients for whom a convergent procedure approach is indicated
- Describe the convergent procedure and the role of electrophysiologist and surgeon
- Discuss current clinical understanding of the convergent procedure including emerging data and the role of the left atrial appendage in ablation
Convergent procedure: A new approach to atrial fibrillation ablation
- 1.00 EBAC
Published:
Learning objectives
- After this session electrophysiologists will be able to identify the causes of sub-optimal outcomes in atrial ablation, describe the convergent procedure and appropriate patients, and outline the electrophysiologist’s role.
Current and Emerging Data on SGLT2 Inhibitors in Heart Failure
- 1.00 EBAC
Published:
Learning objectives
- Understand the SGLT2 inhibitor cardiovascular outcome trial (CVOT) data;
- differentiate the latest guideline updates for the treatment of T2D and their recommendations regarding the importance of considering comorbidities, including atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF);
- apply clinical and real-world evidence of the SGLT2 inhibitor class for use in prevention of hospitalisation in HF, as well as future ongoing studies in the treatment of HF;
- assess the interrelationships linking diabetes, HF and CVD;
- interpret the potential cardio-renal mechanisms of the SGLT2 inhibitor class in reducing the risk of CV, including HF. Evaluate emerging data of the treatment of HF with SGLT2 inhibitors in patients with or without T2DM.
CVD and Type 2 Diabetes: Navigating Therapeutic Boundaries in GLP-1 RA Use
- 2 EBAC
Published:
Learning objectives
- Describe the burden of ASCVD in type 2 diabetes
- Assign risk of future CV events to individuals with type 2 diabetes
- Identify appropriate patients for GLP-1 RA therapy based on clinical trial outcome data to reduce ASCVD risk
- Recall trial data of anti-diabetes medications that reduce ASCVD risk
- Recall the pleiotropic effects of GLP-1 RAs and how these may impact CV outcomes
- Describe how early adoption of anti-diabetes therapies with proven CV benefit can positively influence QOL
- Adopt anti-diabetic therapies with proven ASCVD benefit
Dual antiplatelet therapy for acute stroke and TIA
- 1.00 EBAC
Published:
Learning objectives
- To highlight the continued high unmet need for strategies to prevent stroke or death for patients experiencing acute stroke or TIA
- To outline the guidelines on the use of dual antiplatelet therapy for patients presenting with acute stroke or TIA
- To examine recent evidence from clinical trials on novel strategies for improving outcomes for patients presenting with acute stroke or TIA and how these data and insights can be applied in clinical practice
Examining a Complex Heart Failure Case
- 1 EBAC
Published:
Learning objectives
- Identify individuals likely to have HFpEF from initial presentation
- Refer suspected individuals for specialist assessment
- Initiate GDMT for HF as soon as patients are stable
- Initiate GDMT in HF regardless of EF and phenotype
- Initiate shared decision-making on complex HF patients with other members of the multidisciplinary team including cardiologists, GPs, nephrologists and diabetologists
Most Recent
Examining a Complex Heart Failure Case
- 1 EBAC
Published:
Learning objectives
- Identify individuals likely to have HFpEF from initial presentation
- Refer suspected individuals for specialist assessment
- Initiate GDMT for HF as soon as patients are stable
- Initiate GDMT in HF regardless of EF and phenotype
- Initiate shared decision-making on complex HF patients with other members of the multidisciplinary team including cardiologists, GPs, nephrologists and diabetologists
CVD and Type 2 Diabetes: Navigating Therapeutic Boundaries in GLP-1 RA Use
- 2 EBAC
Published:
Learning objectives
- Describe the burden of ASCVD in type 2 diabetes
- Assign risk of future CV events to individuals with type 2 diabetes
- Identify appropriate patients for GLP-1 RA therapy based on clinical trial outcome data to reduce ASCVD risk
- Recall trial data of anti-diabetes medications that reduce ASCVD risk
- Recall the pleiotropic effects of GLP-1 RAs and how these may impact CV outcomes
- Describe how early adoption of anti-diabetes therapies with proven CV benefit can positively influence QOL
- Adopt anti-diabetic therapies with proven ASCVD benefit